Growth Retardation In Children With Special Pathological Conditions Or Disease
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Pfizer
Related studies linked through entity extraction aliases.
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
- Status
- COMPLETED
- Phase
- PHASE3
A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
- Status
- COMPLETED
- Phase
- PHASE3
A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
- Status
- COMPLETED
- Phase
- PHASE2
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
- Status
- COMPLETED
- Phase
- PHASE2
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
- Status
- COMPLETED
- Phase
- PHASE4
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
- Status
- COMPLETED
- Phase
- PHASE4
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
- Status
- COMPLETED
- Phase
- N/A
Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants
- Status
- COMPLETED
- Phase
- PHASE3
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
- Status
- COMPLETED
- Phase
- PHASE2
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
- Status
- COMPLETED
- Phase
- PHASE3
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
- Status
- COMPLETED
- Phase
- PHASE3
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
- Status
- COMPLETED
- Phase
- PHASE3
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
- Status
- COMPLETED
- Phase
- PHASE2
Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years
- Status
- COMPLETED
- Phase
- PHASE4
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3